Cardiac troponins

Objective: To review the use of cardiac troponins as biomarkers for myocardial injury in human and veterinary medicine. Data sources: Data sources included scientific reviews and original research publications. Human data synthesis: Cardiac troponins have been extensively studied in human medicine. Finding an elevated cardiac troponin level carries important diagnostic and prognostic information for humans with cardiovascular disease. Troponin assays are used primarily to diagnose acute myocardial infarction in patients with ischemic symptoms such as chest pain. However, elevated blood levels may be found with any cause of myocardial injury. Veterinary data synthesis: Several studies have shown that cardiac troponins are sensitive and specific for myocardial damage in veterinary patients and may have utility in diagnosis and prognosis for certain disease states. Human assays may be used in most animals due to significant homology in the troponin proteins between species. Conclusions: Cardiac troponins are sensitive and specific markers of myocardial injury although they do not give any information regarding the mechanism of injury. They have redefined how acute myocardial infarction is diagnosed in humans. Their use in the clinical management of veterinary patients is limited at this time. Further prospective studies are warranted.     

Juniper Consumption Does Not Adversely Affect Meat Quality in Boer-Cross Goats

Goat browsing can be used as an alternative brush management option for redberry (Juniperus pinchotii Sudw.) and ashe (Juniperus asheii Buch) juniper instead of more expensive and invasive brush control methods, assuming consumption of juniper does not adversely affect the marketability of offspring. Some wildlife species reportedly retain juniper flavor when consumed. We determined if juniper consumption affected meat quality or flavoring of Boer-cross kid carcasses. Twenty recently weaned, Boer-cross wethers were randomly assigned to one of four treatments with treatments fed different amounts of juniper (0%, 10%, 20%, 30% juniper in the diet). All goats were fed juniper for 28 d at the Angelo State University (ASU) Management, Instruction, and Research Center. All goats were also fed a feedlot ration to meet maintenance requirements (2% body weight). Juniper intake varied (P < 0.05) between all treatments (0%, 10%, 20%, 30%) primarily because treatments were fed different amounts of juniper. Following a 28-d trial, goats were harvested at the ASU Food Safety and Product Development Laboratory. Carcass characteristics including live weight, hot carcass weight, dressing percentage, loineye area, body wall fat thickness, and leg circumference were similar (P > 0.05) among treatments. Sensory characteristics including tenderness, juiciness, flavor intensity, off-flavor, and overall acceptability were also similar (P > 0.05) among treatments. Landowners can utilize goats as a biological management tool without adversely affecting goat meat quality or flavoring.     

Occurrence of 14 cases of bovine spongiform encephalopathy in a closed dairy herd

Fourteen cases of bovine spongiform encephalopathy (BSE) were diagnosed on the basis of clinical examination in a closed herd of British Friesian cows during a 9-month period from October 1987 until June 1988. The diagnosis was confirmed on histopathological examination of brain tissue from five of the six samples submitted. The main presenting clinical signs were of altered behaviour: apprehension, anxiety and hyperaesthesia. One cow was euthanized after a short period of recumbency; the remaining 13 cows were slaughtered on humane or economic grounds. No protein of animal origin had been fed to either heifers or cows in this herd during the past 5 years and there had been no direct contact with sheep. The epidemiology of BSE in this report suggests that, if the postulate of Morgan (1988) is correct, infection is ingested within the first 6 months of life and there then follows a 4-5-year period before clinical signs appear.     

Treatment of feline hypertension with transdermal amlodipine: a pilot study

This prospective study evaluated transdermal amlodipine for the control of hypertension in six cats. Cats were treated with oral amlodipine until blood pressures decreased to <180 mm Hg. They were maintained on this dose for 7 days and then administered identical doses of transdermal amlodipine for 7 days. Oral amlodipine decreased pressure by a median of 73 mm Hg, which subsequently increased by 20 mm Hg after 7 days of transdermal amlodipine. Plasma concentrations of amlodipine were measured after oral and transdermal dosing. Additional studies are needed to determine dosing, pharmacokinetics, and efficacy.